Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo presents pivotal data from triple combination antihypertensive

This article was originally published in Scrip

Executive Summary

Daiichi Sankyo's triple combination antihypertensive met its primary endpoint in a pivotal trial, show data presented this week at the American Society of Hypertension meeting in New York. CS-8635 (olmesartan plus hydrochlorothiazide plus amlodipine), which combines an angiotensin II receptor blocker, a diuretic and a calcium channel blocker, was filed last year in both the EU and the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC008704

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel